Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer. - Traphagen NA; Wheeler E; Li R; Akhshi T; Ravindranathan R; Alfieri C; Lu F; Ahmed B; Tewari AK; Balk SP; Nelson PS; Corey E; et al. (Proceedings of the National Academy of Sciences of the United States of America, 2026)